VISTAGEN THERAPEUTICS INC (VTGN)
US92840H4002 - Common Stock
Taking everything into account, VTGN scores 3 out of 10 in our fundamental rating. VTGN was compared to 588 industry peers in the Biotechnology industry. VTGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VTGN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VTGN had negative earnings in the past year.
VTGN had a negative operating cash flow in the past year.
VTGN had negative earnings in each of the past 5 years.
VTGN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -24.47%, VTGN is doing good in the industry, outperforming 77.27% of the companies in the same industry.
VTGN's Return On Equity of -26.01% is amongst the best of the industry. VTGN outperforms 82.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.47% | ||
| ROE | -26.01% | ||
| ROIC | N/A |
ROA(3y)-128.39%
ROA(5y)-189.79%
ROE(3y)-203.65%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VTGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
VTGN has more shares outstanding than it did 1 year ago.
VTGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VTGN has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.38 indicates that VTGN is not in any danger for bankruptcy at the moment.
VTGN has a Altman-Z score of 6.38. This is amongst the best in the industry. VTGN outperforms 83.08% of its industry peers.
VTGN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, VTGN perfoms like the industry average, outperforming 50.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.38 |
ROIC/WACCN/A
WACC9.28%
2.3 Liquidity
VTGN has a Current Ratio of 30.76. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 30.76, VTGN belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
VTGN has a Quick Ratio of 30.76. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
VTGN has a Quick ratio of 30.76. This is amongst the best in the industry. VTGN outperforms 98.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 30.76 | ||
| Quick Ratio | 30.76 |
3. Growth
3.1 Past
The earnings per share for VTGN have decreased strongly by -202.45% in the last year.
VTGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 392.06%.
EPS 1Y (TTM)-202.45%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q85.33%
Revenue 1Y (TTM)392.06%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q128.56%
3.2 Future
Based on estimates for the next years, VTGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.64% on average per year.
Based on estimates for the next years, VTGN will show a very strong growth in Revenue. The Revenue will grow by 349.65% on average per year.
EPS Next Y81.16%
EPS Next 2Y33.01%
EPS Next 3Y22.03%
EPS Next 5Y13.64%
Revenue Next Year2691.54%
Revenue Next 2Y130.99%
Revenue Next 3Y-25.99%
Revenue Next 5Y349.65%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
VTGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VTGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VTGN's earnings are expected to grow with 22.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.01%
EPS Next 3Y22.03%
5. Dividend
5.1 Amount
VTGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VISTAGEN THERAPEUTICS INC
NASDAQ:VTGN (4/19/2024, 7:23:20 PM)
After market: 4.8086 +0.05 (+1.02%)4.76
+0.06 (+1.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap128.66M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.47% | ||
| ROE | -26.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 30.76 | ||
| Quick Ratio | 30.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-202.45%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y81.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)392.06%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y